Cargando…

Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation

BACKGROUND: Ablation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear. OBJECTIVE: To compare changes in AF-related healthcare utili...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Daniel J., Field, Michael E., Rahman, Motiur, Goldstein, Laura, Sha, Qun, Sidharth, M., Khanna, Rahul, Piccini, Jonathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183841/
https://www.ncbi.nlm.nih.gov/pubmed/34113902
http://dx.doi.org/10.1016/j.hroo.2020.12.017
_version_ 1783704456199667712
author Friedman, Daniel J.
Field, Michael E.
Rahman, Motiur
Goldstein, Laura
Sha, Qun
Sidharth, M.
Khanna, Rahul
Piccini, Jonathan P.
author_facet Friedman, Daniel J.
Field, Michael E.
Rahman, Motiur
Goldstein, Laura
Sha, Qun
Sidharth, M.
Khanna, Rahul
Piccini, Jonathan P.
author_sort Friedman, Daniel J.
collection PubMed
description BACKGROUND: Ablation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear. OBJECTIVE: To compare changes in AF-related healthcare utilization and costs from preablation to postablation among patients with PAF and PsAF. METHODS: Patients (2794 PAF, 1909 PsAF) undergoing ablation (2016–2018) were identified using the Optum database. Outcomes included inpatient admissions, emergency department (ED) visits, office visits, cardioversion, and antiarrhythmic drug (AAD) use. Costs (2018 US$) and outcomes were compared for the year before/after ablation using the McNemar test and Wilcoxon signed rank test. RESULTS: Compared to PAF patients, PsAF patients were older (68.6 ± 9.0 years vs 67.4 ± 9.9 years, P < .0001), were less commonly female (36.3% vs 44.1%, P < .0001), and more commonly had a CHA(2)DS(2)-VASc ≥ 3(71.2% vs 62.7%, P < .0001). The 12-month postablation costs were lower for AF-specific inpatient admissions (PAF -28%, PsAF -33%), ED visits (PAF -76%, PsAF -70%), AAD prescription fills (PAF -25%, PsAF -7%), and cardioversions (PAF -59%, PsAF -55%) as compared to 12 months before ablation. Although these reductions were observed for both PAF and PsAF patients, absolute costs remained higher for PsAF. Total AF costs were higher during the 1 year after ablation vs before ablation (PAF: 11%, P < .0001; PsAF: 10%, P < .0001) owing to repeat ablation. However, in the 18-month follow-up analysis, postablation costs were overall reduced (PAF: 35%, P < .0001; PsAF: 34%, P < .0001), despite including costs from repeat ablation. CONCLUSION: Significant reductions in healthcare utilization and costs were observed among PAF and PsAF patients undergoing ablation. These data suggest a strategy of earlier ablation may reduce long-term healthcare utilization and costs.
format Online
Article
Text
id pubmed-8183841
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81838412021-06-09 Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation Friedman, Daniel J. Field, Michael E. Rahman, Motiur Goldstein, Laura Sha, Qun Sidharth, M. Khanna, Rahul Piccini, Jonathan P. Heart Rhythm O2 Clinical BACKGROUND: Ablation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear. OBJECTIVE: To compare changes in AF-related healthcare utilization and costs from preablation to postablation among patients with PAF and PsAF. METHODS: Patients (2794 PAF, 1909 PsAF) undergoing ablation (2016–2018) were identified using the Optum database. Outcomes included inpatient admissions, emergency department (ED) visits, office visits, cardioversion, and antiarrhythmic drug (AAD) use. Costs (2018 US$) and outcomes were compared for the year before/after ablation using the McNemar test and Wilcoxon signed rank test. RESULTS: Compared to PAF patients, PsAF patients were older (68.6 ± 9.0 years vs 67.4 ± 9.9 years, P < .0001), were less commonly female (36.3% vs 44.1%, P < .0001), and more commonly had a CHA(2)DS(2)-VASc ≥ 3(71.2% vs 62.7%, P < .0001). The 12-month postablation costs were lower for AF-specific inpatient admissions (PAF -28%, PsAF -33%), ED visits (PAF -76%, PsAF -70%), AAD prescription fills (PAF -25%, PsAF -7%), and cardioversions (PAF -59%, PsAF -55%) as compared to 12 months before ablation. Although these reductions were observed for both PAF and PsAF patients, absolute costs remained higher for PsAF. Total AF costs were higher during the 1 year after ablation vs before ablation (PAF: 11%, P < .0001; PsAF: 10%, P < .0001) owing to repeat ablation. However, in the 18-month follow-up analysis, postablation costs were overall reduced (PAF: 35%, P < .0001; PsAF: 34%, P < .0001), despite including costs from repeat ablation. CONCLUSION: Significant reductions in healthcare utilization and costs were observed among PAF and PsAF patients undergoing ablation. These data suggest a strategy of earlier ablation may reduce long-term healthcare utilization and costs. Elsevier 2020-12-15 /pmc/articles/PMC8183841/ /pubmed/34113902 http://dx.doi.org/10.1016/j.hroo.2020.12.017 Text en © 2020 Published by Elsevier Inc. on behalf of Heart Rhythm Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical
Friedman, Daniel J.
Field, Michael E.
Rahman, Motiur
Goldstein, Laura
Sha, Qun
Sidharth, M.
Khanna, Rahul
Piccini, Jonathan P.
Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title_full Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title_fullStr Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title_full_unstemmed Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title_short Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
title_sort catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183841/
https://www.ncbi.nlm.nih.gov/pubmed/34113902
http://dx.doi.org/10.1016/j.hroo.2020.12.017
work_keys_str_mv AT friedmandanielj catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT fieldmichaele catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT rahmanmotiur catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT goldsteinlaura catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT shaqun catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT sidharthm catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT khannarahul catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation
AT piccinijonathanp catheterablationandhealthcareutilizationandcostamongpatientswithparoxysmalversuspersistentatrialfibrillation